Watch RIGL. Know when insiders buy.
One email the day a filing lands. Free.
RIGL
RIGEL PHARMACEUTICALS INC
48.18
+0.29 +0.61%
USD · close Sep 25
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
52
WATCH · shorts 52
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $900MP/E 2.9DIV YIELD —FCF YIELD —REV TTM $276.8M +3.3%NET INCOME $321.9M +229.1%NET CASH $15.8M52W 25.44 – 50.96SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $78.7M | −22.6% | 89.2% | $23.6M | $17.3M | −71.0% | 0.88 | $30.7M | — | — | Aug 4 |
| Q1 2026 · Mar 31 | $58.8M | +10.3% | 92.2% | $11.9M | $8.7M | −24.4% | 0.44 | $2.7M | — | — | Aug 4 |
| Q4 2025 · Dec 31derived | $69.8M | +21.2% | 91.5% | $23.2M | $268.1M | +1769.2% | 14.10 | $22M | — | — | Mar 3 |
| Q3 2025 · Sep 30 | $69.5M | +25.6% | 93.2% | $28.4M | $27.9M | +124.6% | 1.46 | $24M | — | — | Nov 4 |
| Q2 2025 · Jun 30 | $101.7M | +176.0% | 95.6% | $61.1M | $59.6M | — | 3.28 | $30.5M | — | — | Aug 4 |
| Q1 2025 · Mar 31 | $53.3M | +80.6% | 91.7% | $12.8M | $11.4M | — | 0.63 | −$893K | — | — | Aug 4 |
| Q4 2024 · Dec 31derived | $57.6M | +60.9% | 89.9% | $16.7M | $14.3M | +1845.9% | 0.81 | $14.5M | — | — | Mar 3 |
| Q3 2024 · Sep 30 | $55.3M | +96.6% | 85.5% | $14.1M | $12.4M | — | 0.70 | $21.7M | — | — | Nov 4 |
| Q2 2024 · Jun 30 | $36.8M | — | 92.4% | $447K | −$1M | — | -0.06 | $302K | — | — | Aug 5 |
| Q1 2024 · Mar 31 | $29.5M | — | 93.1% | −$7M | −$8.2M | — | -0.47 | −$5M | — | — | May 6 |
| Q4 2023 · Dec 31derived | $35.8M | — | 89.4% | $2M | $737K | — | 0.05 | −$6.2M | — | — | Mar 3 |
| Q3 2023 · Sep 30 | $28.1M | — | 95.5% | −$4.5M | −$5.7M | — | -0.33 | −$1.4M | — | — | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $294.3M | 93.3% | $125.5M | $367M | 124.7% | 19.48 | $75.7M | — | — | — | — |
| FY2024 · to Dec 31 | $179.3M | 89.6% | $24.2M | $17.5M | 9.8% | 0.99 | $31.5M | — | — | — | — |
| FY2023 · to Dec 31 | $116.9M | 93.9% | −$20.5M | −$25.1M | -21.5% | -1.44 | −$5.7M | — | — | — | — |
| FY2022 · to Dec 31 | $120.2M | 98.5% | −$55.5M | −$58.6M | -48.7% | -3.44 | −$73.8M | $450K | −$74.2M | — | — |
| FY2021 · to Dec 31 | $149.2M | 99.3% | −$12.5M | −$17.9M | -12.0% | -0.11 | $5.9M | $627K | $5.3M | — | — |
| FY2020 · to Dec 31 | $108.6M | 99.2% | −$29M | −$29.7M | -27.4% | -0.18 | −$52.2M | $1.3M | −$53.4M | — | — |
Every number comes from RIGEL PHARMACEUTICALS INC's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.